PMG
TARO icon

ProVise Management Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

ProVise Management Group’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,347
Closed -$243K – 340
2013
Q2 		$243K Buy
+4,347
New +$257K 0.07% 272

Other funds holding TARO

AIM
Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ProVise Management Group's TARO Position: Q3 2013 in Review

ProVise Management Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2013, closing a stake of 4,347 shares — an estimated $243K sold.

ProVise Management Group first reported a position in TARO in Q2 2013 and held it in 1 quarter. The position peaked at $243K in Q2 2013. 47 funds tracked by Wall St. Rank hold TARO as of Q3 2013.

  • ProVise Management Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2013 after selling out during the quarter.
  • ProVise Management Group sold 4,347 Taro Pharmaceutical Industries Ltd. shares in Q3 2013, an estimated $243K.
  • ProVise Management Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and held it in 1 quarter.
  • ProVise Management Group's Taro Pharmaceutical Industries Ltd. position peaked at $243K in Q2 2013.
  • 47 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2013.

Based on ProVise Management Group's 13F filing for Q3 2013, filed 12 Nov 2013.